|Articles|February 1, 2008

Merck gets approval for intravenous antiemetic

Merck extends its Emend line with a new intravenous form

Emend (aprepitant) has now been approved as an injection. Emend (fosaprepitant dimeglumine) for Injection is designed to be used in combination with other antimetics to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately or highly emetogenic cancer chemotherapy, including high-dose cisplatin. Emend for Injection (115 mg) may replace 125 mg oral capsule of Emend on Day 1 and is administered 30 minutes prior to the initiation of chemotherapy over a 15-minute period. This dosage is followed by Emend (80 mg orally) on Days 2 and 3 in a three-day antiemetic regimen, in addition to a corticosteroid and a 5-HT3 antagonist.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, .

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related to this article

September 30th, 2026

Study Links Oral Menopausal Hormone Therapy to Thrombotic Risk

A study of women aged 50 to 69 years found that thrombotic risk varied by route of administration, estradiol dose, and duration of use.

Public Health Solutions, Rural Health Care, Appalachia

September 30th, 2026

Q&A: Why Rural Pharmacies Prioritize Trust Over Technology

Despite technology fostering a new generation of health care delivery, experts believe rural health solutions should be sought elsewhere.

September 30th, 2026

Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version

Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled use, a new study finds.

PAD, peripheral arterial disease, Pharmacist Management of Cardiovascular Disease, MACE, Major Adverse Cardiovascular Events

September 29th, 2026

Pharmacists Are Vital in Complex, Team-Based Treatment of PAD

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

September 29th, 2026

CDC Opens Orders for COVID-19 Vaccines in Vaccines for Children

Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.

mRNA Vaccines, Vaccine Hesitancy, Patient Trust

September 29th, 2026

FAQ: Pharmacist Understanding of mRNA Vaccine Technology

Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.